Pfizer Inc. $PFE Shares Purchased by Persium Advisors LLC

Persium Advisors LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 38.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 27,123 shares of the biopharmaceutical company’s stock after buying an additional 7,589 shares during the quarter. Persium Advisors LLC’s holdings in Pfizer were worth $657,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. Gould Capital LLC boosted its stake in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new position in Pfizer in the 1st quarter valued at about $27,000. North Capital Inc. purchased a new position in Pfizer in the 1st quarter valued at about $28,000. Bayforest Capital Ltd purchased a new position in Pfizer in the 1st quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer during the 4th quarter worth about $30,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 3.8%

Shares of NYSE:PFE opened at $23.91 on Monday. The stock has a 50-day simple moving average of $24.79 and a 200-day simple moving average of $24.27. The stock has a market capitalization of $135.94 billion, a P/E ratio of 12.72, a PEG ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same period in the previous year, the company posted $0.60 earnings per share. Pfizer’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. Pfizer’s dividend payout ratio is presently 91.49%.

Analyst Ratings Changes

A number of research firms have recently weighed in on PFE. HSBC cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a research report on Monday, May 19th. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Berenberg Bank reduced their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Thursday, May 29th. Morgan Stanley lifted their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Finally, Bank of America upped their target price on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.